Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2003

View Archived Issues

Iptakalim, a novel antihypertensive agent, evaluated in rats and dogs

New data on the molecular mechanisms underlying the antitumor activity of MS-275

Raloxifene reduces likelihood of developing osteoporosis and demonstrates uterine safety

Selective iNOS inhibitors show potential in the treatment of endotoxin-induced uveitis

Fluoratec, a DAT imaging agent in clinical development

NS-2330 clinical program extended to Japan

PharmaCare selected as national distributor for Synagis

Aptamera and Archemix enter development and license agreement for AGRO-100

AVI Biopharma seeks orphan drug designation for AVI-4179 in SARS

Change Technology Partners and Neurologix to merge

Genzyme submits regulatory submission for Hylaform

New phase III trial of loteprednol etabonate for allergic rhinitis

Generex receives SBIR grant for HER-2/neu peptide vaccine for breast cancer

Patent Discovery Corp. acquires ADDE rights

New safety information for salmeterol-based drugs

Nymox reviews pipeline

New topoisomerase inhibitors for use in bacterial or fungal infections and cancer

Dual adenosine A1/A2A receptor antagonists and their use claimed by Fujisawa

Japanese researchers isolate new antiinflammatory and antitumor terpenes from plant roots

Schering-Plough and Pharmacopeia team describes new CXC receptor antagonists

Merck patent covers novel insulin receptor kinase activators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...